Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00062504
Status:
TERMINATED
Last Update Posted:
2011-05-23
First Post:
2003-06-06
Brief Title:
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Organization Data
Organization:
Teva Branded Pharmaceutical Products RD Inc
Class:
INDUSTRY
Study ID:
IXR-205-21-189
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Rivka Kreitman PhD Vice President Innovative Research and Development
Old Organization:
Teva Neuroscience
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |